Uncategorized

November 9th, 2011

Shedding Light on Driving in the Dark

From Gary Esterow, Senior Director, Public Relations, VISTAKON® Division of Johnson & Johnson Vision Care, Inc.

On November 6, we turned our clocks back an hour in the United States. For those of us who drive, the end of Daylight Savings Time means more time driving in the dark.

We may not be conscious of it, but when we are behind the wheel, our eyes are constantly on the move – looking at cars ahead and to the side, reading traffic signs, and checking the rearview mirror.  Then our eyes shift to objects a bit closer such as the speedometer, global navigation system and the radio. When it’s dark, these tasks can become much more difficult for some drivers.

As I’ve gotten older, I’ve noticed little changes when I am driving in low-light conditions.  I notice that glare from headlights seems to bother me a bit more and I just get this feeling that my vision could be a bit sharper. I recently went for my annual eye exam and discussed this with my optometrist. A comprehensive eye exam confirmed that my eyes were healthy.  After he checked my vision, we agreed to try a slight change in my contact lens prescription to improve my distance vision.

Read More

November 7th, 2011

Addressing Stroke Risk in Patients with Atrial Fibrillation

By Peter M. DiBattiste, M.D., Global Therapeutic Area Head, Cardiovascular and Metabolism, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

As a cardiologist and music lover, the heart’s constant and rhythmic beat has always been a passion of mine. I’m fascinated by the way that it speeds up when a person is exercising or excited, and the way it slows down during periods of rest.

Sometimes, though, the heart does not contract the way that it should. The beat can become very fast and irregular, in a condition known as atrial fibrillation. This is the most common cardiac rhythm disorder, affecting more than 2.2 million people in the United States, and may leave patients feeling weak, faint, and short of breath. Some patients may not feel any symptoms at all. The irregular heartbeat also leaves people with atrial fibrillation vulnerable to forming blood clots in the heart’s atria, which can potentially travel to the brain, resulting in a stroke.  

Patients with atrial fibrillation are at a five-fold increased risk for stroke compared with the general population. Recommended treatments are available to help reduce this risk of stroke, including medications that thin the blood to help prevent the formation of clots. Despite these recommendations, studies show that nearly half of patients with this condition do not receive appropriate medication.This is important to think about, because the results of stroke are potentially devastating, and take a serious physical, emotional, and financial toll on both the patients and their families.

Read More

July 28th, 2011

Why Becoming A Member of the BDR Matters

From Ruben Taborda, Vice President and Chief Procurement Officer, Medical Devices & Diagnostics group, Johnson & Johnson

I am often asked to explain what drives our commitment to supplier diversity. My answer is usually the same—enhancing our supplier network supports job creation in our communities and connects us to the patients and doctors we serve. This simple response explains why we are so determined to become leaders in this space. Although there is no true end goal (we can always get better at what we do), I believe our recent membership into the Billion Dollar Roundtable (BDR) shows how far we have come.

For those unfamiliar, the BDR is a small group of corporations that have each achieved at least $1 billion in spending with diverse suppliers. Johnson & Johnson earned this membership credential at year’s end in 2010, with $1065 MM total spending with minority and women-owned businesses.

As of July 28, we became the first healthcare company to join this group, joining member companies such as AT&T, IBM and Dell Inc. Our journey began in 2007, when we initiated a multi-year strategy to reach the billion dollar target. Business leaders across the enterprise fully endorsed this objective and within three years time, diverse spending with women- and minority-owned businesses increased by 40 percent.

Read More

July 19th, 2011

Bridging Dreams

From Grace Gervacio, Human Resources and Contributions Director, Johnson & Johnson Philippines

In my role as Contributions Director for J&J Philippines, I have found that the sense of personal fulfillment seems to know no bounds.  But among all the meaningful engagements I have been privileged to experience, I have found no greater fulfillment than from seeing Aizel, Febe and Melanie, three students at a high school in our community in Paranaque, embark on a landmark journey towards a health care career.

These three young ladies are the first scholars of J&J Philippines’ Bridge to Employment (BTE) program.  BTE, a Johnson & Johnson program launched in 1992, provides mentoring to high school students to help prepare them for college and, ultimately, for future careers in the health care industry.   J&J Philippines was tapped to be the first site in Asia to launch this program.  In recognition of the socio-economic conditions in the country, a scholarship component was added to the local program.  Chosen among 20 students who went through the full set of activities such as internships and mentoring by J&J health care professionals, these youngsters will be going through a 2-year midwifery course before returning to Paranaque to serve the community as members of the City Health Office. 

Read More

July 19th, 2011

Johnson & Johnson and “Our Global Giving”

Sharon D’Agostino, Vice President, Worldwide Corporate Contributions & Community Relations, visiting the AED Girls Education program that Johnson & Johnson supports in Dar es Salaam, Tanzania.

From Sharon D’Agostino, Vice President, Worldwide Corporate Contributions and Community Relations, Johnson & Johnson

Johnson & Johnson has a long tradition of Corporate Giving that is inspired by Our Credo responsibility to communities around the world.  Each year we publish “Our Global Giving,” an annual report that showcases the philanthropic work our Company does, working closely with our community-based partners.  The report also highlights the work of Johnson & Johnson colleagues who share the goal of making life-changing, long-term differences in human health. 

In 2010, we supported nearly 700 programs in more than 50 countries, and while these numbers underscore our commitment to local solutions for improving health, they do not capture the many, many personal stories of those who do this work and those who are touched by it.  I am fortunate and grateful to meet some of these people and am always deeply moved by these visits. 

“Our Global Giving” celebrates all of our partners, and though it is not possible to highlight the work of all programs, we have captured examples that provide a representation of the breadth of programs across our three focus areas — saving and improving the lives of women and children, building the skills of people who serve community health needs, and preventing disease and reducing stigma. 

Read More

July 15th, 2011

The Evolution of Social Media: EVO 2011 Conference

From Susan Can, Director, Corporate Equity, Johnson & Johnson Global Marketing Group

On the weekend of July 7th, I had the pleasure of attending the EVO conference where Johnson & Johnson was one of the corporate sponsors.   Set in the scenic mountains of Park City, Utah, this was an amazing experience for us. We were able to meet and talk with so many people who are making a difference in the world by harnessing the power of the internet.

While many bloggers at the conference cover topics related to home, family and health, many also cover topics related to using social media for social good: using the power of the internet to champion specific causes to make a difference.  We were there to engage with attendees on this shared topic of interest – using, “Social Media for Social Good.” 

Visitors to the Johnson & Johnson suite were introduced to three varied aspects of what is happening in the world of social media and Johnson & Johnson.  We introduced &you™ (a brand new digital tool for social good – more on that below).  Participants were able to learn about specific causes that Johnson & Johnson supports, as well as given an opportunity to share their story on how they use social media for social good.

Read More

July 11th, 2011

Using Innovation to Meet Health Care Needs in Asia

From Michael del Prado, Company Group Chairman, Medical Devices & Diagnostics, Asia-Pacific.

The other week, I attended the opening of the Johnson & Johnson Medical Companies Innovation Center in Suzhou, China, our first medical devices and diagnostics innovation center in China and our second in Asia.  The opening of this center comes at a very special time for Johnson & Johnson — during our 125th anniversary year — and it continues one of our oldest traditions as a company:  working to meet unmet health care needs. 

The Asia-Pacific region of the world where I live and work is home to almost 60 percent of the world’s population, but many people in these emerging economies lack access to quality health care.   That’s something we want to help change. 

Johnson & Johnson has been doing business in China, India and other Asian countries for a very long time, first selling our products through local distributors and later opening operating companies in Asia, well ahead of many other multinationals.  We’ve had companies in China since 1982, but access to many of our products centered around the main population centers like Shanghai or Beijing.   The Suzhou Innovation Center will allow us to better serve the millions of men, women and children outside of the main population centers in China who are now gaining access to some degree of healthcare coverage. 

Read More

June 30th, 2011

Johnson & Johnson Recognized at the 2011 Dosie Awards

From Ray Jordan, Corporate Vice President, Public Affairs and Corporate Communication, Johnson & Johnson

The 2011 Dosie Awards, which aim to highlight some of the best examples of social media in the healthcare industry, were recently announced and I’m proud to say Johnson & Johnson was named Company of the Year in Social Media based on the awards received by many of our social media properties, including: the Johnson & Johnson Network page on Facebook, the Johnson & Johnson health channel on YouTube, the @JNJStories Twitter feed, Diabetes Handprint, Children with Diabetes and the JNJ BTW corporate blog. I wanted to take a moment to congratulate all our J&J team members who drive, challenge and nurture our presence in the social media space.

We’re always focusing on what we can do better, so it’s pretty humbling to receive such honor and praise for our social media work. It has been an interesting journey for all of us here at Johnson & Johnson as we figure out the best ways to join the online conversation about health care. As we continue to participate in and learn about the social media space, we hope to find new and innovative ways to engage with you and earn your respect every day.

Read More

June 29th, 2011

2011 Dr. Paul Janssen Award for Biomedical Research Honors Biotechnology Pioneer

By Paul Stoffels, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

Biotechnology has come a long way since the discovery of recombinant DNA almost 40 years ago and the sequencing of the human genome a decade ago.  Today, the term has a broader definition: biomarkers, antibodies, genomics, protemics, RNA, novel scaffolds, peptides, cell therapies, and more, all to help us solve the most important diseases of our time. One example of such an advance is the treatment of angiogenesis, the process of new blood vessel formation that plays a key role in cancer proliferation and a number of other diseases.  These treatments have improved the lives of millions of patients.

Dr. Napoleone Ferrara, Genentech Fellow, has been influential in the development of anti-angiogenesis treatments. Through the identification of a human vascular endothelial cell growth factor (VEGF), he discovered there may be a ways to control the blood supply to particular parts of the body. His innovative work on angiogenesis opened the door to the development of a new class of therapeutics to combat a serious eye disorder and contributed to the development of new oncology therapeutics.

Today Johnson & Johnson honored Dr. Napoleone Ferrara with the 2011 Dr. Paul Janssen Award for Biomedical Research, an award that recognizes passionate and creative scientists like Dr.

Read More

June 28th, 2011

Response to Recent Coverage in the Financial Times

Today’s Financial Times included a story (subscription required) about Johnson & Johnson’s comprehensive approach to preventing and treating disease. The story contained a number of inaccuracies, which Johnson & Johnson addressed in a letter to the Financial Times editors. Here is what we had to say.

Dear Editor of the Financial Times:

Today’s Financial Times included an article about the comprehensive approach of Johnson & Johnson to the prevention and treatment of significant chronic diseases. The story contained a number of inaccuracies.

While Johnson & Johnson believes the breadth of its business interests across consumer, diagnostics and pharmaceuticals business segments is a valuable advantage in its approach to the treatment of a number of chronic conditions, including cancer, the company does not intend to market consumer and regulated products more closely, as reported. In a discussion with the Financial Times, company executives talked about how leaders from the various business segments share insights that improve their understanding of the needs of patients with cancer and other conditions, and, presumably, result in products and services that better meet these needs. They did not, however, state or suggest that the company would market such products together.

Sincerely,

Bill Price
Vice President, Media Relations
Johnson & Johnson

Read More